Bank of America
VIR icon

Bank of America’s Vir Biotechnology VIR Stock Holding History

Bank of America’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,500
Closed -$588K – 8665
2021
Q3 		$588K Buy
+13,500
New +$584K ﹤0.01% 5525

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bank of America's VIR Position: Q1 2026 in Review

Bank of America increased its Vir Biotechnology (VIR) stake by 3.7% in Q1 2026, buying an estimated $278K and bringing the position to 965,814 shares worth $8.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

Bank of America first reported a position in VIR in Q4 2019 and has held it in 26 quarters since. The position peaked at $14.2M in Q1 2023. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Bank of America held 965,814 shares of Vir Biotechnology worth $8.65M as of Q1 2026.
  • Bank of America bought 34,906 Vir Biotechnology shares in Q1 2026, an estimated $278K.
  • Vir Biotechnology made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3082 holding.
  • Bank of America first reported a position in Vir Biotechnology in Q4 2019 and has held it in 26 quarters since.
  • Bank of America's Vir Biotechnology position peaked at $14.2M in Q1 2023.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.